Despite advances in testing, fewer than one of every six people evaluated for suspected neurosarcoidosis — sarcoidosis affecting the nervous system — received a definite diagnosis of the inflammatory disorder, according to a 30-year study in Sweden. A confirmed neurosarcoidosis diagnosis in those cases was made only following a…
News
Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people with sarcoidosis, according to a paper by the Foundation for Sarcoidosis Research (FRS). The white paper was titled “Ignore No More Campaign on Clinical Trials…
Bellerophon Therapeutics is working toward launching a new Phase 2 trial to test INOpulse, its experimental device for inhaled nitric oxide, in people who develop pulmonary hypertension as a complication of sarcoidosis (PH-Sarc). The announcement was part of a company’s clinical program update that stated…
About six months with Acthar Gel were associated with greater therapeutic benefits than a placebo in people with pulmonary sarcoidosis receiving standard-of-care therapies, including glucocorticoids, data from a Phase 4 trial show. The benefits were sustained in those who continued treatment in an extension phase and became evident…
Swelling of a specific vein in the brain may be a sign of neurosarcoidosis, a form of sarcoidosis that affects the nervous system, a new study suggests. “Incorporating this in the current diagnostic criteria may result in timely intervention, and we encourage radiologists to look for this marker in patients…
Only about half of sarcoidosis patients showing signs of muscle disease, or myopathy, have the small clumps of immune cells in their muscles that characterize sarcoidosis, a study showed. When these clumps, called granulomas, weren’t present with muscle symptoms, myopathy was most often linked to inclusion body myositis (IBM),…
The risk of sarcoidosis is significantly reduced in people who smoke cigarettes and may be increased in people who are obese, a study in Sweden suggested. While these findings are consistent with some previous studies, more research is needed to confirm them, the researchers noted in “Modifiable lifestyle…
A lung bleeding condition called diffuse alveolar hemorrhage (DAH) may develop secondary to sarcoidosis more frequently than previously reported, a small study suggests. Considering the frequency of DAH associated with sarcoidosis reported in the study, “it is essential to consider sarcoidosis in the differential diagnosis of immune-mediated DAH,” the researchers…
The Foundation for Sarcoidosis Research (FSR) is offering ways to participate in National Sarcoidosis Awareness Month, observed each April, to call attention to sarcoidosis and the 175,000 U.S. residents thought to be living with the disease. Despite advances in research, sarcoidosis remains challenging to diagnose and…
In advance of Sarcoidosis Awareness Month in April, the Foundation for Sarcoidosis Research (FSR) and aTyr Pharma will hold a virtual town hall about sarcoidosis and considerations for transitioning from standard corticosteroids to new therapies. The meeting, which is open to anyone, will be held online at…
Recent Posts
- Kaleidoscope sparks new Sarcoidosis Awareness Month campaign
- Using our role as ‘professional patients’ to learn and pay it forward
- Most deaths in hospitalized sarcoidosis patients linked to other causes
- A night of nostalgia proves compassion counts with chronic illness
- 2 factors linked to higher risk of death for lung sarcoidosis patients in study
- Autoimmune diseases tied to higher sarcoidosis risk, new study finds
- Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial
- How do you celebrate Autoimmune Awareness Month?
- New congressional caucus to advocate for sarcoidosis research, funding
- Free virtual conference aims to empower sarcoidosis community